Canada Approves 15-Minute Test to Combat Sepsis and Superbugs

OTTAWA, ON – March 25, 2026 – Canadian healthcare providers are about to gain a powerful new tool in the escalating war against sepsis and antimicrobial resistance (AMR). Health Canada has granted a Medical Device License for MeMed BV®, a groundbreaking diagnostic test that can distinguish between a bacterial and a viral infection from a small blood sample in just 15 minutes.

The approval for the test, which runs on the compact MeMed Key® platform, introduces a critical innovation to a system grappling with the severe consequences of diagnostic uncertainty. In emergency rooms and clinics across the country, the inability to quickly determine an infection's origin can lead to delayed treatment for life-threatening bacterial conditions like sepsis, or the unnecessary prescription of antibiotics for viral illnesses, fueling the superbug crisis.

MeMed, an Israeli-American company specializing in host-response technology, developed the test to address this challenge head-on. By analyzing the patient's own immune response rather than searching for a pathogen, the technology provides a rapid and highly accurate signal, empowering clinicians to make faster, more informed treatment decisions.

A New Weapon in a Worsening Fight

The timing of this approval could not be more critical for Canada. Sepsis, the body’s overwhelming and life-threatening response to an infection, is a significant driver of mortality, contributing to approximately one in every 18 deaths nationwide. Simultaneously, the threat of antimicrobial resistance continues to grow.

According to the Public Health Agency of Canada, AMR is already responsible for thousands of deaths annually, and projections are grim. A 2019 report from the Council of Canadian Academies warned that if resistance to first-line antibiotics continues to rise, AMR could cause 13,700 deaths per year in Canada by 2050 and cost the national economy a cumulative $388 billion.

At the heart of this dual crisis is the problem of diagnostic uncertainty. When a patient presents with a high fever and other signs of acute infection, clinicians are often forced to make a judgment call. Prescribing antibiotics “just in case” is a common practice, but it contributes directly to AMR. Conversely, withholding antibiotics from a patient with a developing bacterial infection, such as sepsis or pneumonia, can have catastrophic consequences.

"This approval marks a significant milestone in bringing innovative diagnostics to Canadian clinicians and patients," said Troy Boutelle, President of MeMed USA, in a statement. "In settings where early identification of bacterial infections, particularly those that may progress to sepsis, is critical, MeMed BV delivers actionable insights within minutes."

Decoding the Body's Immune Signals

Unlike traditional laboratory cultures that can take days to yield a result, MeMed BV® is part of a new class of diagnostics that focuses on the host response. Instead of hunting for a specific bacterium or virus, it measures the levels of three specific proteins in the patient's blood: TRAIL, IP-10, and C-reactive protein (CRP). The device's sophisticated algorithm then integrates these measurements into a single, simple score that indicates the likelihood of a bacterial or viral infection.

This multi-marker approach has shown superior performance compared to older, single-biomarker tests like those for CRP or procalcitonin (PCT) alone, which have often proven unreliable in distinguishing between infection types. The technology represents a significant shift from asking "what pathogen is present?" to the more clinically immediate question: "Is the body fighting a bacterial or viral invader?"

MeMed BV® is the first host-immune response test of its kind to receive clearance from the U.S. Food and Drug Administration (FDA), and its effectiveness is supported by extensive global data. The technology has already been used to support the care of over 100,000 patients at more than 200 healthcare sites worldwide.

From Clinical Trials to Real-World Impact

The evidence backing MeMed BV® extends beyond diagnostic accuracy to tangible improvements in patient care and health system efficiency. Peer-reviewed studies and real-world data have demonstrated its potential to dramatically reduce antibiotic misuse and improve outcomes.

One large-scale study showed that implementing the test led to a 63% reduction in unnecessary antibiotic prescriptions. Critically, the same study found that it helped correctly identify 70% of bacterial infections that might have otherwise been missed, leading to a fourfold reduction in subsequent hospitalization rates for that group.

Further research points to significant economic benefits. Health economic models from the UK and US project substantial cost savings per patient, driven by reduced antibiotic use, fewer hospital admissions, and shorter lengths of stay. For a strained Canadian healthcare system, these efficiencies are as crucial as the clinical benefits.

"Together with our partners at Diasorin, we are enabling broader adoption of MeMed BV and supporting healthcare systems in delivering faster, more informed care while advancing antimicrobial stewardship," Boutelle added.

A Strategic Rollout for Nationwide Access

The plan for introducing MeMed's technology in Canada is designed for maximum flexibility and reach. The approval covers not only the rapid, point-of-care MeMed Key® device but also enables the test to be run on the high-throughput LIAISON® platform from diagnostics giant Diasorin, a key partner.

This creates a powerful "hub-and-spoke" model. The compact MeMed Key® can be deployed in emergency departments, urgent care clinics, and physician's offices for immediate, on-the-spot results. Meanwhile, large, centralized hospital labs can use the Diasorin LIAISON® analyzers to process hundreds of samples, integrating the test into their standard workflow.

Jeff Kormos, VP and General Manager at Diasorin Canada, highlighted the synergy of this approach. "As adoption grows in central labs, expanding access in decentralized and frontline care settings will be critical to unlocking the full clinical and operational value of this approach across Canada," he stated.

This strategic partnership aims to ensure that whether a patient is in a major urban hospital or a remote clinic, they can benefit from this advanced diagnostic insight. As MeMed continues its global expansion, the Canadian launch represents another key step in its mission to translate the complex signals of the immune system into simple, actionable insights that can fundamentally change how diseases are diagnosed and managed.